P2RY1

(redirected from platelet ADP receptor)

P2RY1

A gene on chromosome 3q25.2 that encodes a G protein-coupled receptor that acts as a receptor for extracellular ATP and ADP. In platelets, P2RY1 binding to ADP leads to mobilisation of intracellular calcium ions by activating phospholipase C, a change in platelet shape and platelet aggregation.
Mentioned in ?
References in periodicals archive ?
This active metabolite inhibits platelet aggregation by irreversibly binding to platelet ADP receptor P2Y12.
Bochsen and colleagues in 43 healthy blood donors found that platelet ADP receptor inhibition ranged from 0% to 58%, respectively, in healthy controls (Bochsen et al.
Several trials has demonstrated the reduction of cardiovascular risks by dual anti-platelet therapy with the combination of aspirin and clopidogrel, a theinopyridine that causes irreversible inhibition of the platelet ADP receptor P2Ysub12.
This is because the thrombin generated in the TEG cup, which is mandatory for normal fibrin formation, activates platelets through a pathway independent of both cyclooxygenase and the platelet ADP receptor.
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
Several large trials demonstrated improved risk reduction by dual antiplatelet therapy with aspirin and clopidogrel, a thienopyridine that causes irreversible inhibition of the platelet ADP receptor [P2Y.
First the introduction of the thienopyridine derivatives against the platelet ADP receptor in conjunction with aspirin dramatically reduced the incidence of subacute thrombosis.
Millennium also hopes to advance its platelet ADP receptor blocker and its PDGF receptor blocker to development status in 2002.
Although it was initially assumed that the COLADP CT would detect the effect of platelet ADP receptor antagonists, this has proved not to be the case.
Antiplatelet agents in development are listed for those targeting the platelet ADP receptor and the protease-activated receptor-1 (PAR-1) / thrombin receptor as well as for antagonists of GP IIb/IIIa alone or as dual antagonists including a second target.